- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07314164
Estudio de Cabozantinib en Participantes con Tumores Neuroendocrinos que Ya Han Recibido Tratamiento Previo (CaboLife)
CaboLife: Un Estudio Prospectivo No Intervencionista sobre la Efectividad y Seguridad de Cabozantinib en un Entorno de Vida Real para Pacientes con Tumor Neuroendocrino Previamente Tratados
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).
These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.
The study will take place in regular hospitals and clinics in Germany and Austria.
It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life.
This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ipsen Clinical Study Enquiries
- Número de teléfono: See e mail
- Correo electrónico: clinical.trials@ipsen.com
Ubicaciones de estudio
-
-
-
Aschaffenburg, Alemania
- Reclutamiento
- MVZ am Klinikum Aschaffenburg
-
Berlin, Alemania
- Reclutamiento
- Evangelische Lungenklinik Berlin
-
Berlin, Alemania
- Reclutamiento
- DRK Kliniken Berlin
-
Berlin, Alemania
- Reclutamiento
- Charité - Universitaetsmedizin Berlin
-
Bonn, Alemania
- Aún no reclutando
- Johanniter-Kliniken Bonn
-
Bremen, Alemania
- Reclutamiento
- Krankenhaus St. Joseph-Stift Bremen GmbH
-
Chemnitz, Alemania
- Aún no reclutando
- Klinikum Chemnitz
-
Cologne, Alemania
- Reclutamiento
- pioh Studien und Mangement GbR
-
Cologne, Alemania
- Reclutamiento
- MVZ fuer Haematologie und Onkologie Koeln am Sachsenring
-
Dresden, Alemania
- Reclutamiento
- Gemeinschaftspraxis Haematologie - Onkologie
-
Dresden, Alemania
- Reclutamiento
- Technische Univiersitaet (TU) Dresden
-
Erlangen, Alemania
- Reclutamiento
- Universitaetsklinikum Erlangen
-
Essen, Alemania
- Reclutamiento
- Universitaetsklinikum Essen
-
Frankfurt, Alemania
- Aún no reclutando
- Krankenhaus Nordwest
-
Frankfurt am Main, Alemania
- Aún no reclutando
- Uniklinikum Frankfurt
-
Freiburg im Breisgau, Alemania
- Reclutamiento
- Universitaetsklinikum Freiburg
-
Giesen, Alemania
- Aún no reclutando
- Universitaetsklinikum Giessen-Marburg
-
Goettigen, Alemania
- Reclutamiento
- Universitaetsmedizin Goettingen
-
Hamburg, Alemania
- Reclutamiento
- Universitaetsklinikum Hamburg-Eppendorf
-
Hamburg, Alemania
- Aún no reclutando
- Asklepios Kliniken Hamburg
-
Heidelberg, Alemania
- Aún no reclutando
- Universitaetsklinikum Heidelberg
-
Kiel, Alemania
- Aún no reclutando
- UKSH Kiel
-
Leer, Alemania
- Aún no reclutando
- Studienzentrum UnterEms
-
Leipzig, Alemania
- Aún no reclutando
- MVZ Leipzig Mitte, MVZ Delitzsch
-
Leipzig, Alemania
- Aún no reclutando
- Universiteatsmedizin Leipzig
-
Ludwigsburg, Alemania
- Reclutamiento
- RKH Kliniken Ludwigsburg-Bietigheim gGmbH
-
Lübeck, Alemania
- Aún no reclutando
- UKSH Luebeck
-
Mainz, Alemania
- Aún no reclutando
- Universitaetsmedizin Mainz
-
Marburg, Alemania
- Reclutamiento
- Philipps-Universitaet Marburg
-
Minden, Alemania
- Reclutamiento
- Johannes Wesling Klinikum Minden der Muehlenkreiskliniken AoeR
-
Mülheim, Alemania
- Reclutamiento
- MVZ Muelheim an der Ruhr GmbH
-
München, Alemania
- Aún no reclutando
- TUM Klinikum Muenchen
-
Münster, Alemania
- Aún no reclutando
- Universitaetsklinikum Muenster
-
Osnabrück, Alemania
- Aún no reclutando
- MVZ Onkologie Klinikum Osnabrueck GmbH
-
Saarbrücken, Alemania
- Aún no reclutando
- Universitaestklinikum Saarbruecken
-
Tübingen, Alemania
- Reclutamiento
- Universitätsklinikum Tuebingen
-
Westerstede, Alemania
- Reclutamiento
- Medizinische Studiengesellschaft Nord-West
-
Würzburg, Alemania
- Reclutamiento
- Universitaetsklinikum Wuerzburg
-
-
-
-
-
Graz, Austria
- Reclutamiento
- Medizinische Universitaet Graz
-
Linz, Austria
- Aún no reclutando
- Kepler Universitaetsklinikum GmbH Linz
-
Vienna, Austria
- Reclutamiento
- Medizinische Universität Wien
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
150 adult participants in Austria and Germany who are prescribed cabozantinib tablets for unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues prior to entry into the study will be included.
Descripción
Inclusion Criteria:
Participants can join the study if they meet all of the following conditions:
- Are 18 years or older and able to give informed consent.
- Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
- Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
- Have already received at least one prior systemic therapy, other than somatostatin analogues.
- Have signed a written informed consent form.
Exclusion Criteria:
Participants cannot join the study if:
- They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
- They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Disease Control Rate (DCR)
Periodo de tiempo: At 6 Months
|
Proportion of participants who achieve complete response, partial response, or stable disease within 6 months of cabozantinib treatment, based on radiographic assessments performed as part of routine care. |
At 6 Months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective Response Rate (ORR)
Periodo de tiempo: Up to 18 Months
|
Proportion of participants who achieve complete or partial response based on radiographic assessments. |
Up to 18 Months
|
|
Change from baseline in global and subscale scores of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)
Periodo de tiempo: Baseline and Every 3 Months up to 18 Months
|
A validated 30-item questionnaire designed to assess the general health-related quality of life of cancer patients. It includes: 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) a global health status/QoL scale and several single items (e.g., dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). |
Baseline and Every 3 Months up to 18 Months
|
|
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors Module (EORTC QLQ-GINET21)
Periodo de tiempo: Baseline and Every 3 Months up to 18 Months
|
A 21-item module developed to supplement the QLQ-C30 for patients with gastrointestinal neuroendocrine tumors (GI-NETs). It includes 5 scales (Endocrine symptoms, Gastrointestinal symptoms, Treatment-related side effects, Social functioning, Disease-related worries) and 5 single items (weight loss, weight gain, muscle and/or bone pain, information, sexual functioning). |
Baseline and Every 3 Months up to 18 Months
|
|
Percentage of participants experiencing Adverse Events (AEs), non-serious, drug-related, or serious Adverse Events (SAEs)
Periodo de tiempo: Up to 18 Months
|
An Adverse event (AE) is any untoward medical occurrence, temporally associated with the use of study intervention, whether or not related to the study intervention. |
Up to 18 Months
|
|
Percentage of participants with any dose modification due to AEs.
Periodo de tiempo: Up to 18 months
|
Percentage of participants who experienced at least one dose reduction, interruption, or discontinuation due to adverse events during the study period. |
Up to 18 months
|
|
Duration of treatment (DoT)
Periodo de tiempo: Up to 18 Months
|
Time from first dose to last dose of cabozantinib. |
Up to 18 Months
|
|
Percentage of participants switching to a new line of therapy
Periodo de tiempo: Up to 18 Months
|
Percentage of participants who initiated a new line of therapy during the study period. The type of therapy received after switch will be reported descriptively and is not considered a formal outcome measure. |
Up to 18 Months
|
|
Disease control rate after switch to next line of therapy
Periodo de tiempo: 3 Months After Therapy Switch
|
Proportion of participants achieving complete response, partial response, or stable disease within 3 months after switching to a new therapy, based on radiographic assessment performed as part of routine care. |
3 Months After Therapy Switch
|
|
Chromogranin A Levels
Periodo de tiempo: Baseline and Every 3 Months up to 18 Months
|
Chromogranin A blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Neuron-Specific Enolase blood levels.
Periodo de tiempo: Baseline and Every 3 Months up to 18 Months
|
Neuron-Specific Enolase blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Time to next treatment
Periodo de tiempo: Up to 18 Months
|
Time from first dose of cabozantinib to initiation of subsequent therapy. |
Up to 18 Months
|
|
Progression-Free Survival (PFS)
Periodo de tiempo: Up to 18 Months
|
Time from first dose of cabozantinib to disease progression or death from any cause. |
Up to 18 Months
|
|
Progression-Free Survival Rate at 12 and 18 Months
Periodo de tiempo: At 12 and 18 Months
|
Number of participants without disease progression or death. |
At 12 and 18 Months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Ipsen Medical Director, Ipsen
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CLIN-60000-467
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Marco de tiempo para compartir IPD
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the United States (US) and/or Europe (EU).
Criterios de acceso compartido de IPD
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .